Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering the week ended 10 July.

On the menu this time are developments in Alzheimer’s and NASH, coronavirus antivirals, AbbVie Inc.’s Japan business and HIV prophylaxis.

Stories mentioned in this episode:

(Also see "Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease" - Scrip, 8 Jul, 2020.)

(Also see "No Read-Through Expected: NASH Field Unfazed By Intercept’s FDA Rejection" - Scrip, 3 Jul, 2020.)

(Also see "Amid Supply Concerns, EU Approves Gilead’s Remdesivir" - Scrip, 3 Jul, 2020.)

(Also see "AbbVie Eyes Japan Oncology Growth As Humira Biosimilar Looms" - Scrip, 2 Jul, 2020.)

(Also see "ViiV Thinks It May Get All-Gender Approval For Cabotegravir For PrEP" - Scrip, 7 Jul, 2020.)



Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts